LENSAR Inc (LNSR) Q1 2026 Earnings Call Transcript

Why It Matters

The results demonstrate Bausch + Lomb’s ability to convert top‑line growth into higher‑margin earnings, reinforcing its leadership in the expanding eye‑care market and supporting a more optimistic outlook for shareholders.

Key Takeaways

• Revenue reached $1.244B, up 6% constant currency.
• Adjusted EBITDA rose 59% to $200M, margin 16.1%.
• Premium product mix increased to 26% U.S., 13% global.
• LUMIFY revenue grew 15%, now 70% U.S. market share.
• Guidance lifted: revenue $5.42‑$5.52B, EBITDA $1.01‑$1.06B.

Pulse Analysis

The eye‑care sector is being propelled by demographic shifts—aging populations and rising myopia rates—creating a durable demand tailwind for vision‑care products. Bausch + Lomb’s Q1 performance underscores how a diversified portfolio, spanning contact lenses, dry‑eye therapeutics and premium intraocular lenses, can capture this growth. By leveraging AI across sales, operations and drug discovery, the company is sharpening its competitive edge while reducing cost exposure, a strategy increasingly vital as healthcare spend scrutiny intensifies.

Financially, the quarter delivered a compelling blend of top‑line expansion and margin improvement. Adjusted gross margin climbed to 61.2%, and SG&A efficiency added roughly 340 basis points, reflecting disciplined cost control under the Vision ’27 initiative. Premium mix gains—particularly in daily silicone‑hydrogel lenses and high‑margin IOLs—boosted profitability, while the dry‑eye franchise’s 16% revenue surge illustrates the value of high‑growth, high‑margin therapeutic lines. R&D spending rose 15% to $101 million, signaling continued investment in pipeline assets such as LUMIFY NXT and the CE‑marked seeLYRA platform.

Looking ahead, the raised guidance signals confidence in sustaining 5‑7% constant‑currency revenue growth and approaching a 19% adjusted EBITDA margin. The upcoming national launch of PreserVision AREDS3 expands the addressable AMD market by 17 million patients, and the NDA filing for LUMIFY NXT positions the company for further market share gains in ocular redness relief. While elevated oil costs and short‑term surgical headwinds pose risks, the strategic rebuild of the U.S. surgical field force and the accelerating premium mix suggest a trajectory toward stronger procedural volumes and durable earnings growth through 2028.